세계의 동물용 백신 시장(2023-2030년)

Market Overview

The global animal vaccine market reached US$ 12,089.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 22,404.3 million by 2030. The global animal vaccine market is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030).

Vaccination is vital in preserving animal health and well-being. It has long been proven to be an effective method of lowering disease burden in farm and domestic animals. Animal health and illness prevention programs continue to depend more and more on vaccinations.

The global market for animal vaccines is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the animal vaccine market growth. The increasing adoption of animals and the growing clinical trials for novel vaccines are also driving up demand for animal vaccine market trends.

Market Dynamics

The Rising Research and Development Drive the Growth of the Animal Vaccine Market

Various novel research and developments are being done in the field of animal vaccines. New livestock vaccinations created by researchers with funding from the EU have the potential to minimize antibiotic resistance, increase animal welfare, save money, and lessen the need for chemicals that harm the environment. The EU-funded SAPHIR project made an effort to address the gaps in animal illness prevention by creating fresh, potent vaccinations.

The researchers focused on conditions that cause significant economic losses and a strong demand for antibiotic treatments. Researchers from SAPHIR have identified biomarkers for establishing breeding techniques that incorporate high response to vaccines using the most recent genomic and biostatistical approaches.

In addition, they have used mathematical modeling techniques to forecast how well vaccines will work in practice. They have created vaccination candidates using cutting-edge technologies that can offer wide immunity against recently discovered disease strains. The team has produced animal vaccine candidates for six important livestock infections that impact pigs, chickens, and cattle at the project's conclusion. Hence, the growing research is driving the animal vaccine market size.

Rising Government Initiatives and Novel Product Launches Creates Lucrative Opportunities for Manufacturers

There is a growing animal vaccine market opportunity owing to rising advancements and regulatory approvals and the increasing prevalence of infectious diseases. The rising novel product launches by major key players is also driving the market.

Actions are taken by numerous governmental and non-governmental organizations, such as the trilateral European Union-Japan-US program International Cooperation on Harmonization of Technical Standards for Registration of Veterinary Medicinal Products (VICH), which aims to harmonize the technical specifications for veterinary product registration.

VICH's responsibility is to standardize the technical standards for the information required for a veterinary medical product's marketing authorization. This is accomplished by creating unified standards for the research that must be included in a marketing permission application.

A Lack of Animal Health Awareness will Hamper the Growth of the Market

Animal health is crucial because unhealthy animals can have a wide range of negative effects. Additionally, animal diseases that affect humans can have an effect on other economic sectors such as global trade, agricultural stability, and public health. Hence, the above-mentioned factors will be limiting the animal health market growth over the forecast period.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity for animals.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global animal vaccine market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global animal vaccine market growth over the forecast period.

Segment Analysis

The global animal vaccine market is segmented based on product type, animal type, route of administration and region.

Inactivated Vaccines From Product Type Segment Account for 40.3% of the Market Share Owing to Rising Novel Product Launches

In 2022, the inactivated vaccines segment held a dominant position in the global animal vaccine market. The segment is advantageous because inactivated vaccinations, also known as killed vaccines, are made by killing a pathogen that has been grown and then turned into a vaccine. These vaccines are often used to protect against a variety of bacterial and viral illnesses.

Furthermore, inactivated vaccines elicit powerful immune responses by retaining the inactive genetic element, and the virus surface antigens are essential for a powerful immunological response. Additionally, inactivated immunization is safe and has a higher demand because it doesn't remain in the surroundings or in the fish who have received it.

As a result, there is now a greater need for inactivated aquaculture vaccinations. The market segment is predicted to have the greatest market share during the projection period based on the aforementioned assertions.

Geographical Analysis

North America Accounted For Approximately 39.8% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for animal vaccines for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of animal vaccines, which has increased the demand. North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for animal vaccines.

Rising new drug or infection types will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals, and novel product launches. Researchers are becoming more aware of various kinds of treatment or prevention approaches for infectious disorders, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the animal vaccine market include: Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Services LLC, Ceva, Vetoquinol, Elanco, Veterquimica S.A., Phibro Animal Health Corporation, KBNP, Inc. and Kyoto Biken Laboratories, Inc. among others.

Why Purchase the Report?

• To visualize the global animal vaccine market segmentation based on product type, animal type, route of administration and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of animal vaccine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global animal vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Animal Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Innovation in Animal Vaccine Production
    • 4.1.1.2. The Rising Research and Development
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Animal Health Awareness
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Regulatory Approvals and Novel Product Launches
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Post COVID-19 & Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Modified-live (attenuated) Vaccine *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Inactivated (killed) Vaccine
• 7.4. Recombinant Vaccine
• 7.5. Toxoid Vaccine

8. By Animal Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  • 8.1.2. Market Attractiveness Index, By Animal Type
• 8.2. Companion Animal *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Feline
  • 8.2.4. Canine
  • 8.2.5. Others
• 8.3. Livestock Animal
  • 8.3.1. Poultry
  • 8.3.2. Swine
  • 8.3.3. Cattle
  • 8.3.4. Others
• 8.4. Aquaculture

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Subcutaneous *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Intramuscular
• 9.4. Intranasal

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan

Australia

• 10.5.6.4. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Merck & Co., Inc. *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Boehringer Ingelheim International GmbH
• 12.3. Zoetis Services LLC
• 12.4. Ceva
• 12.5. Vetoquinol
• 12.6. Elanco
• 12.7. Veterquimica S.A.
• 12.8. Phibro Animal Health Corporation
• 12.9. KBNP, Inc.
• 12.10. Kyoto Biken Laboratories, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us